Revolutionising myeloma treatment through immune profiling
Professor Stefan Pfister talks to ecancer about identifying prognostic biomarkers and next generation genomic sequencing at the European Forum on Oncology in Berlin, May 2012.
Working within the German Consortium for Translational Cancer Research, Prof Pfister explains their goals of increasing translational oncology in research and in the clinic. In the future, they hope to exploit sequencing technology in diagnostics so tumour and blood sequencing can take place for each patient.
Revolutionising myeloma treatment through immune profiling
ESMO 2024: Optimising the personalisation of prostate cancer treatment
Multiple myeloma In Rwanda: The need for further research
Addressing the rise of multiple myeloma in Rwanda
GIST tumours and soft tissue sarcomas
Best practice in HRRm testing in patients with metastatic prostate cancer
ELCC 2024: Latest in EGFR mutant lung cancer; exon 20 mutation focus
Multiple myeloma in a resource constrained setting
Remote genetic testing has the potential to increase the uptake of testing in large integrated healthcare systems